Chugai Pharmaceutical Co., Ltd. (FRA:CUP)

Market Cap	73.95B
Revenue (ttm)	6.99B
Net Income (ttm)	2.29B
Shares Out	n/a
EPS (ttm)	1.39
PE Ratio	32.33
Forward PE	n/a
Dividend	1.09 (2.45%)
Ex-Dividend Date	Jun 27, 2025

Volume	n/a
Average Volume	30
Open	44.48
Previous Close	44.30
Day's Range	44.37 - 44.50
52-Week Range	33.02 - 53.18
Beta	n/a
RSI	49.39
Earnings Date	Jan 29, 2026

About Chugai Pharmaceutical

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Polivy, Tecentriq, and Phesgo; Neutrogin and Sigmart; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept for immunosuppressant; Edirol, an osteoporosis agent; Enspryng, a pH-dependent binding humanized anti-IL-6 re...

• Industry: Pharmaceutical Preparations
• Founded: 1925
• Employees: 5,026
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: CUP

Financial Performance

In 2024, Chugai Pharmaceutical's revenue was 1.17 trillion, an increase of 5.33% compared to the previous year's 1.11 trillion. Earnings were 387.32 billion, an increase of 19.00%.

Financial numbers in JPY